SUMMARY We studied the effects of afterload reduction in chronic severe aortic insufficiency by measuring the hemodynamic response to oral hydralazine in 10 consecutive patients. Hemodynamics were also measured during maximal exercise in eight of these patients. At rest, hydralazine reduced pulmonary artery wedge pressure from 14 to 9 mm Hg (p < 0.01), and increased cardiac index by 70% and stroke volume index by 35% (both p < 0.001). Before hydralazine, pulmonary artery wedge pressure exceeded 20 mm Hg in five patients during maximal exercise; with hydralazine, at identical levels of exercise, pulmonary artery wedge pressure remained below 20 mm Hg in all patients. For the group, hydralazine reduced pulmonary artery wedge pressure from 21 to 12 mm Hg (p < 0.05) and increased cardiac index by 31% (p < 0.05) during exercise; changes in stroke volume index were more variable and there was no significant increase for the group, although several patients increased stroke volume substantially and the overall increase was 34%.
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These data show that afterload reduction has beneficial effects on cardiac performance in chronic severe aortic insufficiency both at rest and during exercise. Hydralazine may be of use in such patients either in preparation for valve replacement or as interim therapy.
THE USEFULNESS of vasodilators in the treatment of patients with congestive heart failure has been demonstrated.'-" By virtue of their ability to unload the heart, vasodilators improve pump function at rest and appear to have beneficial effects on exercise performance and functional class.'1012 Depending on their site of action, vasodilators may result in a reduction in preload or afterload or both.
Nitroprusside, a drug that reduces both preload and afterload,13 has been shown to improve cardiac performance in patients with aortic insufficiency.14' 15 Because nitroprusside requires continuous monitoring, its use is limited to the intensive care unit setting. Although oral afterload-reducing agents are available, the effects of isolated afterload reduction in aortic insufficiency are uncertain.
To assess the potential of afterload reduction in the management of patients with aortic insufficiency, we evaluated the effects of oral hydralazine on cardiac performance at rest and during exercise in a group of patients with chronic severe aortic insufficiency.
Methods

Patient Population
Ten consecutive patients with chronic severe aortic insufficiency were evaluated. All patients had undergone cardiac catheterization at our institution within l month of the study and had chronic severe aortic insufficiency on the basis of angiographic and 
where S is the peak systolic and D the diastolic pressure. Systemic vascular resistance (SVR, dyn-seccm-5) was derived from the formula: 
Statistical Analysis
The paired t test was used to compare values before and after hydralazine for the resting and exercise states. Exercise values were compared for the same external work load. Linear regression analysis was used to evaluate the relationship between control period systemic vascular resistance during maximal exercise and reduction in pulmonary artery wedge pressure after hydralazine.
Results
Rest
The effects of oral hydralazine on resting pressures and flow are shown in table 2 and figure 1. Heart rate, mean arterial pressure and right atrial and pulmonary artery pressures did not change significantly with hydralazine, although heart rate tended to increase and arterial pressure and pulmonary artery pressure tended to decrease. Pulmonary artery wedge pressure decreased significantly, from 14 to 9 mm Hg. The largest reduction in both pulmonary artery and pulmonary artery wedge pressures occurred in patients in whom control values were most markedly elevated (table 2, (table 3) . The relationship during exercise between systemic vascular resistance during the control period and the reduction in pulmonary wedge pressure after hydralazine is shown in figure 2 . Patients who maintained the highest resistance during control exercise showed the greatest reduction in wedge pressure after treatment. There was no significant difference in VO during exercise between control and posthydralazine levels (table 3) .
Discussion
This study shows that in patients with chronic severe aortic insufficiency, afterload reduction with hydralazine improves cardiac performance both at rest and during exercise. At rest, hydralazine resulted in a decrease in pulmonary artery and pulmonary artery wedge pressures. Although pulmonary artery wedge pressure fell in all 10 patients, the most striking changes were seen in patients whose control values were initially the highest (table 2, patients 3, 6 and 8). A similar trend was noted in pulmonary artery pressures, although changes for the group were not significant. Cardiac index increased 70% above control measurements. Stroke volume index also increased significantly; however, the magnitude of change was not as great as with cardiac index due to a tendency for heart rate to increase after hydralazine. Only two of 10 patients did not have an appreciable increase in stroke volume index in response to hydralazine. In patient 7 (table 2), hydralazine had no appreciable effect on resting flow, but during exercise, stroke volume index increased by 41% (from 44 to 62 ml/m2) above control exercise levels. In patient 6, stroke volume index increased from 35 to 37 m1/mi2.
Because pulmonary artery wedge pressure was reduced from 19 to 3 mm Hg by hydralazine it is conceivable that augmentation of forward flow by afterload reduction was compromised by a reduction in filling pressure (presumably due to a reduction in regurgitant flow). A reduction in end-diastolic fiber stretch would result in a reduction in cardiac output by the Starling mechanism. During exercise, left ventricular filling pressure was markedly reduced by hydralazine therapy. Several patients had shown an increase in pulmonary artery wedge pressure from either normal (tables 2 and 3, patients 1, 5 and 7) or mildly elevated levels (patient 6) at rest to levels above 20 mm Hg during control exercise. In patient 8 Hydralazine probably improves cardiac performance in aortic insufficiency by a combination Qf mechanisms. By virtue of a direct relaxant effect on arteriolar smooth muscle and reduction in systemic vascular resistance,"6-"9 ventricular emptying is facilitated.3 In addition, total left ventricular stroke volume is most likely redistributed in response to the reduction in vascular resistance so that forward flow increases while regurgitant flow declines. Such changes in the distribution of flow have been noted in patients with aortic insufficiency treated with nitroprusside, 4, 15 a drug whose effect on arteriolar resistance is similar to that of hydralazine. Unlike nitroprusside, hydralazine has little or no effect on venous capacitance,3 so the reduction in left ventricular filling pressure seen in our patients was most likely due to a reduction in regurgitant flow; however, other factors need to be considered. Because increases in heart rate alone can reduce left ventricular diastolic volume and pressure,20 hydralazine-induced changes in heart rate may have contributed to the beneficial response seen in our patients. However, the changes in heart rate after hydralazine tended to be small and were somewhat variable. In patients 3 and 9 (table 2), stroke volume index increased and pulmonary artery wedge fell despite a decrease in rate. Improved ventricular emptying with hydralazine might also have contributed to the reduction in filling pressure seen in our patients. However, data from previous studies suggest that when afterload reduction alone is used to treat patients with congestive heart failure, left ventricular filling pressure changes little despite significant improvement in cardiac output.3, 5 In the presence of mitral regurgitation, filling pressure can be reduced by afterload reduction alone because of a significant reduction in regurgitant flow.21'24 Only patients 1 and 3 (table 1) had evidence of mitral regurgitation on left ventricular angiography. In patient 1, the lesion was trivial. Patient 3 had moderate mitral regurgitation, so reduction in filling pressure may have been due at least in part to reduced mitral regurgitation.
For all these reasons we conclude that the beneficial effects of hydralazine in reducing left ventricular filling pressure were largely the result of a reduction in regurgitant flow. Preliminary data from our laboratory in other patients treated with intravenous hydralazine suggest that afterload reduction in aortic insufficiency results in a consistent reduction in regurgitant flow (Greenberg BH, Murphy E, DeMots H, Rahimtoola SH: unpublished observations).
The changes in pressures and flow during exercise in this group of patients probably resulted from the interplay of multiple factors. Whether or not a patient would develop an abnormal elevation of pulmonary artery wedge pressure could not be determined from hemodynamic and angiographic data at catheterization or from control data obtained during rest. Previous reports have shown that in patients with aortic insufficiency, exercise may result in a reduction in the volume overload faced by the left ventricle.25 27 A decrease in diastolic flow period due to an increase in heart rate and a reduction in systemic vascular resistance due to increased muscle demands have been suggested as possible mechanisms whereby regurgitant flow is reduced. During exercise, however, patients with chronic severe aortic insufficiency may have impaired left ventricular function that was not apparent at rest. 28 Although this factor was not assessed in our patients, exercise-induced abnormalities of ventricular function probably contributed to the hemodynamic deterioration in several of our patients. In addition, Zelis et Supine exercise studies in human cardiac transplant recipients have shown a pattern of response similar to that seen during submaximal exercise in animals. Car-diac output is increased during exercise by an initial elevation of stroke volume followed by a gradual rise in heart rate.6 7, 9, 10 Clarke et al. 10 reported that during dynamic exercise in the denervated human, cardiac output increases, first by stroke volume augmentation due to the Starling mechanism and later by enhancement of contractility by circulating catecholamines. In the innervated heart these two mechanisms occur simultaneously. Reports of a diminished cardiac output response for a given level of work accompanied by an elevated arteriovenous oxygen difference suggest that maximal oxygen uptake and exercise tolerance after transplantation may be restricted.9 To document the cardiorespiratory response and exercise capacity of cardiac transplant recipients during symptom-limited treadmill exercise, the following study was performed.
Methods
Subjects
To assess the effect of cardiac transplantation upon exercise capacity, 15 cardiac transplant recipients (12 men and three women) and 14 normal men performed graded, symptom-limited treadmill exercise. The transplant recipients were patients returning to Stanford for their annual evaluation, while the controls were volunteers, similar in age to the cardiac transplant patients, who were asymptomatic for car-55
